

ABIM Laboratory Test Reference Ranges – January 2017	
Laboratory Tests	Reference Ranges
1,25-Dihydroxyvitamin D	See Vitamin D metabolites
(1,25-dihydroxycholecalciferol), serum	
17-Hydroxyprogesterone, serum	
Female, follicular	Less than 80 ng/dL
Female, luteal	Less than 285 ng/dL
Female, postmenopausal	Less than 51 ng/dL
Male (adult)	Less than 220 ng/dL
25-Hydroxyvitamin D	See Vitamin D metabolites
(25-Hydroxycholecalciferol), serum 5-Hydroxyindoleacetic acid, urine	2–9 mg/24 hr
6-Thioguanine, whole blood	-
	230–400 pmol/8x10 <sup>8</sup> RBCs
Absolute neutrophil count (ANC)	2000–8250/μL
Acid phosphatase, serum	
Total	0.5–2.0 (Bodansky) units/mL
Prostatic fraction	0.1–0.4 unit/mL 10–60 pg/mL
ACTH, plasma	1 0
Activated partial thromboplastin time	25–35 seconds
ADAMTS13 activity	Greater than 60%
Adrenocorticotropic hormone (ACTH), plasma	10–60 pg/mL
Albumin, serum	3.5–5.5 g/dL
Albumin, urine	Less than 25 mg/24 hr
Albumin-to-creatinine ratio, urine	Less than 30 mg/g
Aldolase, serum	0.8-3.0 IU/mL
Aldosterone, plasma	
Supine or seated	Up to 10 ng/dL
Standing	Less than 21 ng/dL
Low-sodium diet (supine)	Up to 30 ng/dL
Aldosterone, urine	5–19 μg/24 hr
Alkaline phosphatase, serum	30–120 U/L
Alkaline phosphatase, bone specific	5.6–18.0 μg/L for premenopausal women
Alpha <sub>1</sub> -antitrypsin (AAT), serum	150–350 mg/dL
Alpha <sub>2</sub> -antiplasmin activity, plasma	75%-115%
Alpha-amino nitrogen, urine	100–290 mg/24 hr
Alpha-fetoprotein, serum	Less than 10 ng/mL
Amino acids, urine	200–400 mg/24 hr
Aminotransferase, serum alanine (ALT, SGPT)	10–40 U/L
Aminotransferase, serum aspartate (AST, SGOT)	10–40 U/L
Ammonia, blood	40–70 µg/dL
Amylase, serum	25–125 U/L (80–180 [Somogyi] units/dL)
Amylase, urine	1–17 U/hr
	· · ·
Androstenedione, serum	Female: 30–200 ng/dL; male: 40–150 ng/dL
Angiotensin-converting enzyme, serum	8–53 U/L
Anion gap, serum	7–13 mEq/L
Antibodies to double-stranded DNA	0–7 IU/mL

Anticardiolipin antibodies	
l · · · · · · · · · · · · · · · · · · ·	Less than 20 GPL
IgG	Less than 20 MPL
IgM	
Anti-cyclic citrullinated peptide, antibodies to	Less than 20 units
Antideoxyribonuclease B	Less than 280 units
Anti-F-actin antibodies, serum	1:80 or less
Antihistone antibodies	Less than 1:16
Anti-liver-kidney microsomal antibodies (anti-LKM)	Less than 1:20
Antimitochondrial antibodies	1:5 or less
Anti–myelin associated glycoprotein antibody	Less than 1:1600
Antimyeloperoxidase antibodies	Less than 3.0 U/mL
Antinuclear antibodies	1:40 or less
Anti–smooth muscle antibodies	1:80 or less
Antistreptolysin O titer	Less than 200 Todd units
Antithrombin activity	80%–120%
Antithyroglobulin antibodies	Less than 20 U/mL
Antithyroid peroxidase antibodies	Less than 2.0 U/mL
Arterial blood gas studies (patient	
breathing room air):	
рН	7.38–7.44
PaCO <sub>2</sub>	38–42 mm Hg
PaO₂	75–100 mm Hg
Bicarbonate	23–26 mEq/L
Oxygen saturation	95% or greater
Methemoglobin	0.5%-3.0%
Ascorbic acid (vitamin C), blood	0.4–1.5 mg/dL
Ascorbic acid, leukocyte	16.5 ± 5.1 mg/dL of leukocytes
(1,3)-Beta-D-glucan, serum	Less than 60 pg/mL
Beta subunit chorionic gonadotropin, urine	Less than 2 mIU/24 hr
Beta <sub>2</sub> -glycoprotein antibodies:	
IgG	Less than 21 SGU
IgM	Less than 21 SMU
Beta-hydroxybutyrate, serum	less than 0.4 mmol/L
Beta <sub>2</sub> -microglobulin, serum	0.54–2.75 mg/L
Bicarbonate, serum	23–28 mEq/L
Bilirubin, serum	23-28 IIILY/L
· · · · · · · · · · · · · · · · · · ·	0.3.10 mg/dl
Total	0.3–1.0 mg/dL
Direct	0.1–0.3 mg/dL
Indirect	0.2–0.7 mg/dL
Bleeding time (template)	Less than 8 minutes
Blood urea nitrogen (BUN), serum or plasma	8–20 mg/dL
B-type natriuretic peptide, plasma	Less than 100 pg/mL
C peptide, serum	0.8–3.1 ng/mL
Calcitonin, serum	Female: 5 pg/mL or less; male: 10 pg/mL or less
Calcium, ionized, serum	1.12–1.23 mmol/L
Calcium, serum	8.6–10.2 mg/dL
Calcium, urine	Female: Less than 250 mg/24 hr;
	male: less than 300 mg/24 hr

Carbohydrate antigens, serum	
CA 19-9	0–37 U/mL
CA 27-29	Less than 38.0 U/mL
CA 125	Less than 35 U/mL
Carbon dioxide content, serum	23–30 mEq/L
Carboxyhemoglobin, blood	Less than 5%
Carcinoembryonic antigen, plasma	Less than 2.5 ng/mL
Carotene, serum	75–300 μg/dL
Catecholamines, plasma	
Dopamine	Less than 30 pg/mL
Epinephrine	
Supine	Less than 50 pg/mL
Standing	Less than 95 pg/mL
Norepinephrine	
Supine	112-658 pg/mL
Standing	217–1109 pg/mL
Catecholamines, urine	
Dopamine	65–400 μg/24 hr
Epinephrine Epinephrine	2–24 µg/24 hr
Norepinephrine	15–100 µg/24 hr
Total	26–121 µg/24 hr
CD4 (T4) lymphocyte count	530–1570/μL
Cell count, CSF:	330 1370, μΣ
Leukocytes (WBCs)	0–5 cells/μL
Ceruloplasmin, serum (plasma)	25–43 mg/dL
Chloride, CSF	120–130 mEq/L
Chloride, serum	98–106 mEq/L
Chloride, urine	30 100 mzq/2
Spot	mEq/L; varies
24-hour measurement	mEq/24 hr; varies with intake
Cholesterol, serum	meg/2 m) varies with meake
Total	
Desirable	Less than 200 mg/dL
Borderline-high	200–239 mg/dL
High	Greater than 239 mg/dL
-	Greater triair 239 mg/dL
High-density lipoprotein Low	Female: less than 50 mg/dL;
LOW	male: less than 40 mg/dL
Low-density lipoprotein	maio, iess than to flig/ at
Optimal	Less than 100 mg/dL
Near-optimal	100–129 mg/dL
Borderline-high	130–159 mg/dL
High	160–189 mg/dL
Very high	Greater than 189 mg/dL
Cholinesterase, serum (pseudocholinesterase)	0.5 or more pH units/hr
Packed cells	0.7 or more pH units/hr
Chorionic gonadotropin, beta-human	Female, premenopausal nonpregnant: less than 1.0 U/L;
(beta-hCG), serum	female, postmenopausal: less than 7.0 U/L; male: less
,,,	than 1.4 U/L
Chromogranin A, serum	Less than 93 ng/mL

Citrate, urine	250–1000 mg/24 hr
Clotting time (Lee-White)	5–15 minutes
Coagulation factors, plasma	
Factor I (fibrinogen)	200–400 mg/dL
Factor II (prothrombin)	60%–130%
Factor V (accelerator globulin)	60%–130%
Factor VII (proconvertin)	60%–130%
Factor VIII (antihemophilic globulin)	50%–150%
Factor IX (plasma thromboplastin component)	60%–130%
Factor X (Stuart factor)	60%–130%
Factor XI (plasma thromboplastin antecedent)	60%–130%
Factor XII (Hageman factor)	60%–130%
Cold agglutinin titer	Greater than 1:64 positive
Complements, serum	
C3	100–233 mg/dL
C4	14–48 mg/dL
CH50	110–190 units/mL
Copper, serum	100–200 μg/dL
Copper, urine	0–100 μg/24 hr
Coproporphyrin, urine	50–250 μg/24 hr
Cortisol, free, urine	4–50 μg/24 hr
Cortisol, plasma	
8 AM	5–25 μg/dL
4 PM	Less than 10 μg/dL
1 hour after cosyntropin	18 μg/dL or greater
Overnight suppression test (1-mg)	Less than 1.8 μg/dL
Overnight suppression test (8-mg)	Greater than 50% reduction in cortisol
Cortisol, saliva, 11 PM – midnight	Less than 0.09 μg/dL
C-reactive protein, serum	0.8 mg/dL or less
C-reactive protein (high sensitivity), serum	Low risk = less than 1.0 mg/L; Average risk = 1.0–3.0
	mg/L; High risk = more than 3.0 mg/L
Creatine kinase, serum	
Total	Female: 30–135 U/L; male: 55–170 U/L
MB isoenzymes	Less than 5% of total
Creatine, urine	Female: 0–100 mg/24 hr; male: 0–40 mg/24 hr
Creatinine clearance, urine	90–140 mL/min
Creatinine, serum	0.7–1.5 mg/dL
Creatinine, urine	
Spot	mg/dL; varies
24-hour measurement	15–25 mg/kg body weight/24 hr
Cyclosporine, whole blood (trough)	
Therapeutic range	100–200 ng/mL
0–3 months post transplantation	150–250 ng/mL
More than 3 months post transplantation	75–125 ng/mL
D-dimer, plasma	Less than 0.5 μg/mL
Dehydroepiandrosterone sulfate (DHEA-S), serum	Female: 44–332 μg/dL; male: 89–457 μg/dL
Delta-aminolevulinic acid, serum	Less than 20 μg/dL
Digoxin, serum	Therapeutic range: 1.0–2.0 ng/mL
	(less than 1.2 ng/mL for patients with heart failure)

Adult male: 25–80 ng/dL
Less than 30 pg/mL
65–400 μg/24 hr
25–40 mg/dL
4.5–7.5 g during a 5-hr period
136–145 mEq/L
3.5–5.0 mEq/L
98–106 mEq/L
23–28 mEq/L
Less than 110 pg/mL
Less than 140 pg/mL
Less than 20 μg/24 hr
4.2–5.9 million/μL
Female: 0–20 mm/hr; male: 0–15 mm/hr
T½ = 28 days
4–26 mU/mL
10–180 pg/mL
100–300 pg/mL
40–200 pg/mL
Less than 10 pg/mL
20–50 pg/mL
Greater than 12 mg/24 hr
Negative: Less than 10 fmol/mg protein
10–60 pg/mL
Less than 0.005% (less than 5 mg/dL)
More than 0.5% (more than 500 mg/dL)
0.08%-0.1% or greater (80-100 mg/dL or greater)
2–4 hours at 37.0 C
Therapeutic range: 3.0–8.0 ng/mL
60–130 U/dL
Less than 7 g/24 hr
Less than 2 g/24 hr
7.0–7.5
Less than 10 mEq/L
Less than 10 mEq/L
40–280 mg/24 hr
Less than 250 g/24 hr
Female: 11–211 ng/mL; male: 20–235 ng/mL
Less than 10 μg/mL
200–400 mg/dL
200–400 mg/dL 30–80 RU/mL
-
30–80 RU/mL

Follicle-stimulating hormone, serum	
Female, follicular/luteal	2–9 mIU/mL (2–9 U/L)
Female, mid-cycle peak	4–22 mIU/mL (4–22 U/L)
Female, postmenopausal	Greater than 30 mIU/mL (Greater than 30 U/L)
Male (adult)	1–7 mIU/mL (1–7 U/L)
Children, Tanner stages 1, 2	0.5-8.0 mIU/mL (0.5-8.0 U/L)
Children, Tanner stages 3, 4, 5	1–12 mIU/mL (1–12 U/L)
Free kappa light chain, serum	3.3–19.4 mg/L
Free kappa-to-free lambda light chain ratio, serum	0.26–1.65
Free lambda light chain, serum	5.7–26.3 mg/L
Fructosamine, serum	175–280 mmol/L
Gamma globulin, CSF	6.1–8.3 mg/dL
Gamma-glutamyl transpeptidase, serum	Female: 8–40 U/L; male: 9–50 U/L
Gastric secretion	Terrate: 5 45 672, mate: 5 36 672
Basal acid analysis	10–30 units of free acid
Basal acid ariaysis  Basal acid output	Female: $2.0 \pm 1.8$ mEq of HCl/hr; male: $3.0 \pm 2.0$ mEq of
ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο ο	HCI/hr
Maximal output after pentagastrin stimulation	23 ± 5 mEq of HCl/hr
Gastrin, serum	Less than 100 pg/mL
Gentamicin, serum	Therapeutic range: peak 5.0–10.0 µg/mL;
, , , , , , , , , , , , , , , , , , , ,	trough: less than 2.0 μg/mL
Glucose, CSF	50–75 mg/dL
Glucose, plasma (fasting)	70–99 mg/dL
Glucose-6-phosphate dehydrogenase, blood	5–15 units/g of hemoglobin
Glycoprotein α-subunit, serum	Less than 1 ng/mL
Growth hormone, serum	
At rest	Less than 5 ng/mL
Response to provocative stimuli	Greater than 7 ng/mL
Haptoglobin, serum	83–267 mg/dL
Hematocrit, blood	Female: 37%–47%; male: 42%–50%
Hemoglobin A <sub>1C</sub>	4.0%-5.6%
Hemoglobin, blood	Female: 12–16 g/dL; male: 14–18 g/dL
Hb A	96%–98%
Hb A₂	1.5%-3.5%
Hb F	Less than 1%
Hemoglobin, plasma	Less than 5.0 mg/dL
Heparin–anti-factor Xa assay, plasma	0.3–0.7 IU/mL [therapeutic range for standard
	(unfractionated) heparin therapy]
Heparin–platelet factor 4 antibody	Positive: Greater than 0.4 optical density units
Hepatic copper	25–40 μg/g dry weight
Hepatic iron index	Less than 1.0
Histamine excretion, urine	20–50 μg/24 hr
Homocysteine, plasma	5–15 μmol/L
Beta-human chorionic gonadotropin (beta-hCG),	Female, premenopausal nonpregnant: less than 1.0 U/L;
serum	female, postmenopausal: less than 7.0 U/L; male: less
	than 1.4 U/L
Hydroxyproline, urine	10–30 mg/sq meter of body surface/24 hr
Immature platelet fraction	1%–5% of platelet count
Immune complexes, serum	0–50 μg/dL

Immunoglobulins, serum	
IgA	90–325 mg/dL
lgE	Less than 380 IU/mL
IgG	800-1500 mg/dL
lgM	45–150 mg/dL
Immunoglobulin free light chains, serum	U.
Карра	3.3–19.4 mg/L
Lambda	5.7–26.3 mg/L
Kappa-to-lambda ratio	0.26–1.65
Insulin, serum (fasting)	Less than 20 μU/mL
Insulin-like growth factor 1 (IGF-1)	
(somatomedin-C), serum	
Ages 16–24	182–780 ng/mL
Ages 25–39	114–492 ng/mL
Ages 40–54	90–360 ng/mL
Ages 55 and older	71–290 ng/mL
lodine, urine	
Spot	μg/L; varies
Iron, serum	50–150 μg/dL
Iron-binding capacity, serum (total)	250–310 μg/dL
Lactate dehydrogenase, serum	80–225 U/L
Lactate, arterial blood	Less than 1.3 mmol/L (Less than 1.3 mEq/L)
Lactate, serum or plasma	0.7–2.1 mmol/L
Lactate, venous blood	0.6–1.8 mEq/L; 6–16 mg/dL
Lactic acid, serum	6–19 mg/dL (0.7–2.1 mmol/L)
Lactose tolerance test, GI	Increase in plasma glucose: greater than 15 mg/dL
Lead, blood	15–40 μg/dL
Lead, urine	Less than 80 μg/24 hr
Leukocyte count	4000–11,000/μL
Segmented neutrophils	50%–70%
Band forms	0–5%
Lymphocytes	30%–45%
Monocytes	0–6%
Basophils	0–1%
Eosinophils	0–3%
Lipase, serum	10–140 U/L
Lipoprotein(a) serum	Desirable: less than 30 mg/dL
Lithium, plasma	
Therapeutic range	0.6–1.2 mEq/L
Toxic level	Greater than 2 mEq/L
Luteinizing hormone (LH), serum	
Female, follicular/luteal	1–12 mIU/mL (1–12 U/L)
Female, mid-cycle peak	9–80 mIU/mL (9–80 U/L)
Female, postmenopausal	Greater than 30 mIU/mL (Greater than 30 U/L)
Male (adult)	2–9 mIU/mL (2–9 U/L)
Children, Tanner stages 1, 2, 3	Less than 9.0 mIU/mL (Less than 9.0 U/L)
Children, Tanner stages 4, 5	1–15 mIU/mL (1–15 U/L)

Lymphacyta cubcata	
Lymphocyte subsets CD3	000 2245/11
	900–3245/μL
CD4	530–1570/μL
CD8	430–1060/μL
CD 19 B	208-590/μL
Magnesium, serum	1.6–2.6 mEq/L
Magnesium, urine	14–290 mg/24 hr
Mean corpuscular hemoglobin	28–32 pg
Mean corpuscular hemoglobin concentration	33–36 g/dL
Mean corpuscular volume	80–98 fL
Mean platelet volume	7–9 fL
Metanephrines, fractionated, plasma	
Metanephrine	Less than 0.5 nmol/L
Normetanephrine	Less than 0.9 nmol/L
Metanephrines, fractionated, 24-hour urine	
Metanephrine	Less than 400 μg/24 hr
Normetanephrine	Less than 900 μg/24 hr
Myoglobin, serum	Less than 100 μg/L
Norepinephrine, plasma	
Supine	70–750 pg/mL
Standing	200–1700 pg/mL
Norepinephrine, urine	0–100 μg/24 hr
Normetanephrine, fractionated, plasma	Less than 0.9 nmol/L
Normetanephrine, fractionated, 24-hour urine	Less than 900 μg
N -telopeptide, urine	Female: 11–48 nmol BCE/mmol creatinine;
	male: 7–68 nmol BCE/mmol creatinine
N -terminal-pro-B-type natriuretic peptide (NT-pro-BNP),	If eGFR > 60 mL/min/1.73 m2
serum or plasma	18 –49 years of age
	Heart failure unlikely: 300 pg/mL or less
	High probability of heart failure: 450 pg/mL or
	greater
	50–75 years of age  Heart failure unlikely: 300 pg/mL or less
	High probability of heart failure: 900 pg/mL or
	greater
	Older than 75 years of age
	Heart failure unlikely: 300 pg/mL or less
	High probability of heart failure: 1800 pg/mL or
	greater
	If eGFR < 60 mL/min/1.73 m2
	18 years of age or older
	High probability of heart failure: 1200 pg/mL or
	greater
Osmolality, serum	275–295 mOsm/kg H <sub>2</sub> O
Osmolality, urine	38–1400 mOsm/kg H <sub>2</sub> O
Osmotic fragility of erythrocytes	Increased if hemolysis occurs in over 0.5% NaCl;
Ostoppoloin corrum	decreased if hemolysis is incomplete in 0.3% NaCl
Osteocalcin, serum	Male: 11.3–35.4 ng/mL; Female: 7.2–27.9 ng/mL
Oxalate, urine	Less than 40 mg/24 hr
Oxygen consumption	225–275 mL/min
Oxygen saturation, arterial blood	95% or greater

150–350 pg/mL	Parathyroid hormone, serum  C-terminal
· -	C-leilillai
10–65 pg/mL	Intact
Target: 130–585 pg/mL	Intact (dialysis patients only)
Less than 1.5 pmol/L	Parathyroid hormone-related protein, serum
25–35 seconds	Partial thromboplastin time (activated)
4.5–8.0	pH, urine
At least 25% excreted by 15 minutes;	Phenolsulfonphthalein, urine
40% by 30 minutes;	Thenoisunonphinalem, arme
60% by 120 minutes	
Therapeutic range: 10–20 μg/mL	Phenytoin, serum
	Phosphatase (acid), serum
0.5–2.0 (Bodansky) units/mL	Total
0.1–0.4 unit/mL	Prostatic fraction
30–120 U/L	Phosphatase (alkaline), serum
200–300 mg/dL	Phospholipids, serum (total)
3.0–4.5 mg/dL	Phosphorus, serum
500–1200 mg/24 hr	Phosphorus, urine
150,000–450,000/μL	Platelet count
	Platelet function analysis (PFA-100):
60–143 seconds	Collagen–epinephrine closure time
58–123 seconds	Collagen–ADP closure time
10 days	Platelet survival rate ( <sup>51</sup> Cr)
3.5–5.0 mEq/L	Potassium, serum
	Potassium, urine
mEq/L; varies	Spot
mEq/24 hr; varies with intake	24-hour measurement
16–30 mg/dL	Prealbumin, serum
0.2–3.5 mg/24 hr	Pregnanetriol, urine
70–180 mm CSF (70–180 mm H <sub>2</sub> O)	Pressure (opening) [initial], CSF
less than or equal to 0.10 ng/mL	Procalcitonin, serum
	Progesterone, serum
0.02–0.9 ng/mL	Female, follicular
2–30 ng/mL	Female, luteal
0.12–0.3 ng/mL	Male (adult)
3–20 pmol/L	Proinsulin, serum
Less than 20 ng/mL	Prolactin, serum
ng/mL; no specific normal or abnormal level	Prostate-specific antigen, serum
65%–150%	Protein C activity
70%–140%	Protein C antigen
goal: 1.0–1.2 g/kg/24 hr	Protein catabolic rate, urine
57%–131%	Protein S activity
	Protein S antigen
60%–140%	Total
60%–130%	Free
	Protein, urine
mg/dL; varies	Spot
Less than 100 mg/24 hr	24-hour measurement
15—45 mg/dL	Proteins, CSF total
3.0–4.5 mg/dL 500–1200 mg/24 hr 150,000–450,000/μL  60–143 seconds 58–123 seconds 10 days 3.5–5.0 mEq/L  mEq/L; varies mEq/24 hr; varies with intake 16–30 mg/dL 0.2–3.5 mg/24 hr 70–180 mm CSF (70–180 mm H <sub>2</sub> O) less than or equal to 0.10 ng/mL  0.02–0.9 ng/mL 2–30 ng/mL 0.12–0.3 ng/mL 3–20 pmol/L Less than 20 ng/mL ng/mL; no specific normal or abnormal level 65%–150% 70%–140% goal: 1.0–1.2 g/kg/24 hr 57%–131%  60%–140% 60%–130%  mg/dL; varies Less than 100 mg/24 hr	Phosphorus, serum Phosphorus, urine Platelet count Platelet function analysis (PFA-100): Collagen—epinephrine closure time Collagen—ADP closure time Platelet survival rate (51Cr) Potassium, serum Potassium, urine Spot 24-hour measurement Prealbumin, serum Pregnanetriol, urine Pressure (opening) [initial], CSF Procalcitonin, serum Progesterone, serum Female, follicular Female, luteal Male (adult) Proinsulin, serum Prostate-specific antigen, serum Protein C activity Protein C antigen Protein S activity Protein S antigen Total Free Protein, urine Spot 24-hour measurement

Durataina assuus	
Proteins, serum	5 5 0 0 -/41
Total	5.5–9.0 g/dL
Albumin	3.5–5.5 g/dL
Globulin	2.0–3.5 g/dL
Alpha1	0.2–0.4 g/dL
Alpha2	0.5–0.9 g/dL
Beta	0.6–1.1 g/dL
Gamma	0.7–1.7 g/dL
Protein-to-creatinine ratio, urine	Less than 0.2 mg/mg
Prothrombin time, plasma	11–13 seconds
Pyruvic acid, blood	0.08–0.16 mmol/L
Quinidine, serum	Therapeutic range: 2–5 μg/mL
Red cell distribution width (RDW)	9.0–14.5
Red cell mass	Female: 22.7–27.9 mL/kg; male: 24.9–32.5 mL/kg
Renin activity (angiotensin-I radioimmunoassay)	
Peripheral plasma	
Normal diet	
Supine	0.3–2.5 ng/mL/hr
Upright	0.2–3.6 ng/mL/hr
Low sodium diet	
Supine	0.9–4.5 ng/mL/hr
Upright	4.1–9.1 ng/mL/hr
Diuretics + low sodium diet	6.3–13.7 ng/mL/hr
Renal vein concentration	Normal ratio (high:low): less than 1.5
Reptilase time	10–12 seconds
Reticulocyte count	0.5%–1.5% of red cells
Reticulocyte count, absolute	25,000–100,000/μL
Rheumatoid factor (nephelometry)	Less than 24 IU/mL
Rheumatoid factor, latex test for	1:80 or less
Ristocetin cofactor activity of plasma	50%-150%
Russell viper venom time, dilute	33–44 seconds
Salicylate, plasma	Therapeutic range: 20–30 mg/dL
Sex hormone-binding globulin	Female, nonpregnant: 18–144 nmol/L;
	male: 10–57 nmol/L
Sodium, serum	136-145 mEq/L
Sodium, urine	
Spot	mEq/L; varies
24-hour measurement	mEq/24 hr; varies with intake
Specific gravity, urine	1.002-1.030
Sperm density	10–150 million/mL
Sweat test for sodium and chloride	Less than 60 mEq/L
T3 resin uptake	25%–35%
T4 (CD4) lymphocyte count	530–1570/μL
Tacrolimus, whole blood	Trough therapeutic range: 5–15 ng/mL {For transplant
	patients: 10.0–15.0 ng/mL (0–3 months post
	transplantation);5.0–10.0 ng/mL (more than 3 months
Taskaskasana asuum	post transplantation)}
Testosterone, serum	Female: 18–54 ng/dL; male: 291–1100 ng/dL
Testosterone, bioavailable, serum	Female, age 18–69 yrs: 0.5–8.5 ng/dL
Testosterone, free, serum	Male: 70–300 pg/mL

Theophylline, serum	Therapeutic range: 8–20 μg/mL
Thrombin time	17–23 seconds
Thyroid function studies	
T3 resin uptake	25%–35%
Thyroglobulin, serum	Less than 20 ng/mL
Thyroidal iodine ( <sup>123</sup> I) uptake	5%–30% of administered dose at 24 hours
Thyroid-stimulating hormone (TSH), serum	0.5–4.0 μU/mL (0.5–4.0 mU/L)
Thyroid-stimulating immunoglobulin (TSI)	Less than 130%
Thyroxine-binding globulin, serum	12–27 μg/mL
Thyroxine index, free (estimate)	5–12
Thyroxine (T₄), serum	
Total	5–12 μg/dL
Free	0.8–1.8 ng/dL
Triiodothyronine (T <sub>3</sub> ), serum	
Total	80–180 ng/dL
Reverse	20–40 ng/dL
Free	2.3–4.2 pg/mL
Total proteins, CSF	15–45 mg/dL
Transaminase, serum glutamic oxaloacetic (SGOT)	See aminotransferase, serum aspartate (AST)
Transaminase, serum glutamic pyruvic (SGPT)	See aminotransferase, serum alanine (ALT)
Transferrin saturation	20%–50%
Transferrin, serum	200–400 mg/dL
Triglycerides, serum (fasting)	-
Optimal	Less than 100 mg/dL
Normal	Less than 150 mg/dL
Borderline-high	150-199 mg/dL
High	200–499 mg/dL
Very high	Greater than 499 mg/dL
Troponin I, cardiac, serum	0.04 ng/mL or less
Troponin T, cardiac, serum	0.01 ng/mL or less
Tryptase, serum	Less than 11.5 ng/mL
Urea clearance, urine	
Standard	40–60 mL/min
Maximal	60–100 mL/min
Urea nitrogen, blood	8–20 mg/dL
Urea nitrogen, urine	12–20 g/24 hr
Uric acid, serum	3.0–7.0 mg/dL
Uric acid, urine	250–750 mg/24 hr
Uroporphyrin, urine	10–30 μg/24 hr
Vancomycin, plasma	Therapeutic: 15 to 20 mg/L
Vancomycin, serum	10 to 16 μg/mL
Vanillylmandelic acid, urine	Less than 9 mg/24 hr
Venous oxygen content, mixed	14–16 mL/dL
Venous studies, mixed, blood	
рН	7.32–7.41
PCO2	42–53 mm Hg
PO2	35–42 mm Hg
Bicarbonate	24–28 mEq/L
Oxygen saturation (SvO2)	65%–75%
<u> </u>	

Viscosity, serum	1.4–1.8 cp
Vitamin A, serum:	
Adult	32.5–78.0 μg/dL
Pediatric, age 1–2 yr (retinol)	20–43 μg/dL
Vitamin B <sub>12</sub> , serum	200–800 pg/mL
Vitamin D metabolites, serum	
1,25-Dihydroxyvitamin D	15–60 pg/mL
(1,25-dihydroxycholecalciferol)	
25-Hydroxyvitamin D	20–60 ng/mL
(25-hydroxycholecalciferol)	
Vitamin E, serum:	
Adult	5.5–17.0 mg/L
Pediatric, age 1–2 yr (alpha-tocopherol)	2.9–16.6 mg/L
Volume, blood	
Plasma	Female: 43 mL/kg body weight;
	male: 44 mL/kg body weight
Red cell	Female: 20–30 mL/kg body weight;
	male: 25–35 mL/kg body weight
von Willebrand factor antigen, plasma	50%-150%
Zinc, serum	75–140 μg/dL

Revised - March, 2017